You are using an outdated browser. Please upgrade your browser to improve your experience.

pralsetinib

Ligand Summary
Ligand Structure
Rendered image for the query structure
Description
Pralsetinib is a kinase inhibitor of wild-type RET and oncogenic RET fusions (CCDC6-RET) and mutations (RET V804L, RET V804M and RET M918T) with half maximal inhibitory concentrations (IC50s) less than 0.5 nM. In purified enzyme assays, pralsetinib inhibited DDR1, TRKC, FLT3, JAK1-2, TRKA, VEGFR2, PDGFRb, and FGFR1 at higher concentrations that were still clinically achievable at Cmax. In cellular assays, pralsetinib inhibited RET at approximately 14-, 40-, and 12-fold lower concentrations than VEGFR2, FGFR2, and JAK2, respectively.
Synonyms & Links
Guide to Pharmacology: 10033
DrugCentral: 5412
LyCHI:  3VU8UASRKXFR


Target Activities